Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, open-label comparison of the safety and efficacy of tigecycline with that of ampicillin-sulbactam or amoxicillin-clavulanate to treat complicated skin and skin structure infections

Next Previous
X
Search
Trial Profile

A multicenter, randomized, open-label comparison of the safety and efficacy of tigecycline with that of ampicillin-sulbactam or amoxicillin-clavulanate to treat complicated skin and skin structure infections

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tigecycline (Primary) ; Amoxicillin/clavulanic acid; Ampicillin/sulbactam
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Wyeth

    • Most Recent Events

    • 08 Aug 2012 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 28 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 10 Apr 2010 Results presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top